Caribou Biosciences, Inc. (CRBU)

Every figure this model derived for CRBU, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,359,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 112,314,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 116,595,000 AssetsCurrent 2026-06-30
current liabilities 17,974,000 LiabilitiesCurrent 2026-06-30
equity 98,102,000 StockholdersEquity 2026-06-30
ocf -95,780,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 10,035,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 10,503,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CRBU on one particular measure came for.

RatioValue
cash operating margin-960.46
current ratio6.62
current ratio reported6.49
deferred revenue growth-86.85
dilution pct3.4
fcf margin-968.0
growth cv3.31
operating margin-1090.9
owner earnings margin-1072.67
revenue growth10.02
revenue growth per share6.4
rpo growth-60.87
rule of 40-1080.88
sbc pct revenue104.66

What to be careful about

What this model itself distrusts about CRBU's figures. Written by the derivation as it ran, not added afterwards.